Amedisys (NASDAQ:AMED) Rating Upgrade

Amedisys (NASDAQ:AMED) was raised by Mizuho Securities from “Neutral” rating to “Buy” rating in a research note revealed to clients and investors on Wednesday, 3 May. The firm currently has a $65.0 price target on the stock. Mizuho Securities’s price target gives a potential upside of 15.89 % from the stock’s last close price.

The stock upgrade is welcomed by stock traders, as NASDAQ:AMED is currently trading 1.92% higher at $56.25 as of 12:01 AM New York time. Amedisys shares have [From2] 0% in the last 200 days, while the S&P 500 Index has surged 10.61% in the same time period.

According to data compiled by Thomson Reuters, Amedisys (NASDAQ:AMED)’s stock is covered by 7 equity analysts across the Street, with 0 analysts giving it a Sell rating, 5 a Buy rating, while 4 consider it a Hold. The 12-month consensus target price for the stock is $54.39, which reflects an downside potential of 3.31% over the current price.

Institutional Ownership

Kohlberg Kravis Roberts & Co. L.P. had the most significant stake with ownership of 4.84M shares as of q2 2015 for 2.85% of the fund portfolio. First Light Asset Management Llc is another notably bullish institutional investor who is possessing 112,604 shares of Amedisys or 2.3% of their fund portfolio. In addition, Lombard Odier Asset Management (Switzerland) Sa have 1.59% of their fund portfolio invested in the company for 140,000 shares. The Wisconsin-based fund Timpani Capital Management Llc revealed it had acquired so far a stake worth about 0.9% of the institutional investor’s stock portfolio in Amedisys. The New York-based fund Gilder Gagnon Howe & Co Llc is also positive about the stock, possessing 47,710 shares or 0.73% of their fund portfolio.

Amedisys (NASDAQ:AMED) Profile

Amedisys, Inc. is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services.

Amedisys (NASDAQ:AMED) traded up 1.92% on 3 May, hitting $56.25. A total of 135,279 shares of the company’s stock traded hands. This is down from average of 208,230 shares. Amedisys has a 52 week low of $34.58 and a 52 week high of $56.4. The company has a market cap of $1.93 billion and a P/E ratio of 50.95.

Get the latest Amedisys (NASDAQ:AMED) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.

The post Amedisys (NASDAQ:AMED) was Upgraded by Mizuho Securities from a “Neutral” Rating to “Buy” with $65.0 Target Price per Share appeared first on Octafinance.